---
title: Improve cognitive function with training
nct_id: NCT06323278
status: RECRUITING
sponsor: "Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico"
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06323278"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06323278"
last_fetched: "2026-05-10T14:07:27.416Z"
source: "Parkinson's Pathways (curated)"
---
# Improve cognitive function with training

**Goal (in five words):** Improve cognitive function with training

**Official Title:** Evaluation of the Cognitive Stimulation Treatment in Patients With Parkinson's Disease

**Trial ID:** [NCT06323278](https://clinicaltrials.gov/study/NCT06323278)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- **Target Enrollment:** 68 participants
- **Start Date:** 2021-12-21
- **Completion Date:** 2026-12
- **Conditions:** Parkinson Disease
- **Interventions:** Cognitive training
- **Intervention Types:** BEHAVIORAL

## Summary For Families

The goal is to see whether a structured cognitive stimulation program can help people with Parkinson's who have mild cognitive impairment, by maintaining or improving memory, attention, planning, and everyday thinking. The approach uses regular, non-drug cognitive training sessions,guided exercises and activities meant to stimulate neural networks and strengthen thinking skills,and it is offered alongside usual care, so it does not replace or change levodopa or other medications. The trial is looking for adults 18 to 80 with a Parkinson's diagnosis who have had genetic screening, a MoCA raw score between about 15.5 and 22.23, have given consent, are not diagnosed with dementia, and are not treated with deep brain stimulation.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Patients with Parkinson's disease according to the Gelb et al. criteria;
* Patients who have carried out genetic screening for MP;
* Patients who have a raw score in the range 15.50 to 22.23 at Montreal cognitive assessment (MoCA);
* Patients who have signed the informed consent and the Privacy Policy;
* Patients who are included in cognitive stimulation programs according to regular clinical practice.

Exclusion Criteria:

* Patients with the initial suspicion of MP that during the diagnostic work-up they were suffering from a different pathology;
* Patients who have refused consent to participate in the study;
* Patients with a diagnosis of MP and cognitive profile of dementia;
* Patients undergoing deep brain neurostimulation (DBS-STN) treatment. Patients treated with DBS-STN were excluded because such treatment involves a surgical procedure whose effects on cognitive functioning could represent an interfering variable.
```

## Locations (1)

- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy _(45.4643, 9.1895)_
  - Fabiana Ruggiero, MSc in Psychology — (CONTACT) — +390255033621 — fabiana.ruggiero@policlinico.mi.it

## Central Contacts

- Fabiana Ruggiero, MSc in Psychology — (CONTACT) — +390255033621 — fabiana.ruggiero@policlinico.mi.it
- Francesca Mameli, MSc in Psychology — (CONTACT) — +390255033621 — francesca.mameli@policlinico.mi.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT06323278*  
*HTML version: https://parkinsonspathways.com/trial/NCT06323278*  
*Source data: https://clinicaltrials.gov/study/NCT06323278*